Related Experiment Video
Updated: May 8, 2026
Measuring Neuromuscular Junction Functionality
Published on: August 6, 2017
Congenital myasthenic syndromes: an update
Daniel Hantaï1, Sophie Nicole, Bruno Eymard
1Inserm, U975, Centre de recherche de l'Institut du Cerveau et de la Moelle épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. daniel.hantai@upmc.fr
Recent advances in genetic sequencing have identified new genes causing congenital myasthenic syndromes (CMSs), a neuromuscular junction disorder. Novel therapeutic strategies tailored to specific gene mutations offer promising treatment for CMS patients.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Congenital myasthenic syndromes (CMSs) are a group of genetic disorders affecting neuromuscular transmission.
- Mutations in various genes lead to CMSs, presenting a challenge in diagnosis and treatment.
Purpose of the Study:
- To review recently identified causative genes for CMSs.
- To discuss current and emerging therapeutic strategies for CMSs.
Main Methods:
- Exome sequencing has been instrumental in discovering new genes associated with CMSs.
- Analysis of clinical data and animal models aids in understanding disease pathophysiology.
Main Results:
- New genes identified, including those involved in glycosylation defects, expanding the known genetic basis of CMSs.
- A shift towards gene-specific therapeutic strategies, rather than solely relying on established drugs, is a key advancement.
Conclusions:
- The review highlights recent genetic discoveries and therapeutic approaches for CMSs.
- It emphasizes the diagnostic challenges, including differentiating CMSs from congenital myopathies and recognizing potential overlaps.
More Related Videos
11:07Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
Published on: April 14, 2022
12:18The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
Published on: December 26, 2014
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...